Tag Archive for: myasthenia gravis

The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.

The drug, Zilbrysq is the first once-daily subcutaneous targeted C5 complement inhibitor approved for generalized myasthenia gravis (gMG) and is currently the only self-administered targeting option rare autoimmune disease.

Wednesday, Sanofi released data from a Phase II study showing its investigational anti-CD40L antibody frexalimab met the trial’s primary endpoint and significantly lowered disease activity in patients with relapsing multiple sclerosis. 

Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis (MG), the company announced Friday in its full-year 2022 financial report.

And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. 

The agency’s decision came after researchers found cases of drug-induced liver injury in some patients.

June is Myasthenia Gravis Awareness month. As with so many rare diseases, the standard of care for myasthenia gravis (MG) doesn’t address the root of the illness and comes with side effects that can be serious. Nipocalimab, which is in Phase III development at Janssen, goes to the cause of the disease.